Humacyte Realigns Symvess Rights with Fresenius Medical Care
Humacyte (HUMA) announced that it has realigned the ex-U.S. rights to Symvess through an amendment to its distribution agreement with Fresenius Medical Care (FMS). "We are pleased to have worked successfully with our long-time partner and largest shareholder Fresenius Medical Care, to realign the global rights to Symvess in a manner that benefits both companies and best enables Humacyte's planned international expansion," said Laura Niklason, CEO of Humacyte. "The restructuring of ex-U.S. commercial rights enables us to fully advance the commercial initiatives that we previously announced in the Kingdom of Saudi Arabia and Israel in vascular injury repair and other indications. In addition, we are now positioned to advance discussions with prospective corporate partners regarding international and indication-specific rights to Symvess. As amended, the distribution agreement now provides that Humacyte will have the exclusive rights to distribute Symvess outside the U.S., and FME will be entitled to low-single-digit royalties on our net sales of Symvess outside the U.S. Existing terms related to the U.S. remain unchanged."
